<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003067</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065739</org_study_id>
    <secondary_id>NYWCCC-0902499</secondary_id>
    <secondary_id>NYWCCC-IMMUNE-0902499</secondary_id>
    <secondary_id>SIUH-RP-96-004</secondary_id>
    <secondary_id>NCI-V97-1326</secondary_id>
    <nct_id>NCT00003067</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Primary or Advanced Glioma</brief_title>
  <official_title>Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill&#xD;
      cancer cells in patients with primary or advanced glioma.&#xD;
&#xD;
      PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2&#xD;
      and lymphokine-activated killer cells in treating patients who have primary, recurrent, or&#xD;
      refractory malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Confirm the antitumor efficacy of intracavitary interleukin-2 plus autologous&#xD;
           lymphokine-activated killer cells in patients with primary, recurrent or refractory&#xD;
           malignant gliomas.&#xD;
&#xD;
        -  Determine whether the induction of a regional, intracavitary, eosinophilia is a&#xD;
           prognosticator of response to immunotherapy and long term survival in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive cytoreductive tumor surgery and/or biopsy and implantation of&#xD;
      intracavitary Ommaya reservoir prior to therapy induction.&#xD;
&#xD;
      Patients undergo outpatient leukapheresis on day -4 or -5, and cells are incubated ex vivo&#xD;
      with interleukin-2 (IL-2). Lymphokine-activated killer (LAK) cells and IL-2 are infused on&#xD;
      day 1. Bolus infusions of low-dose IL-2 are administered on days 3, 5, 8, 10, and 12,&#xD;
      followed by a rest period on days 13-24. The course is repeated on day 25 starting with&#xD;
      leukapheresis. Therapy courses are repeated for up to 1 year for stable disease or response&#xD;
      to therapy. Maintenance doses repeat every 4-6 months thereafter.&#xD;
&#xD;
      Disease restaging is done every 8-12 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients per year will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>July 1997</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lymphokine-activated killer cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or radiographically proven primary, recurrent, or refractory malignant&#xD;
             gliomas (glioblastoma, anaplastic astrocytoma, and mixed anaplastic glioma)&#xD;
&#xD;
               -  Must be a candidate for neurosurgical biopsy or tumor debulking&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance Status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life Expectancy:&#xD;
&#xD;
          -  Greater than 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocytes greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 50,000/mm^3&#xD;
&#xD;
          -  PT and PTT within normal limits&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No coronary artery disease&#xD;
&#xD;
          -  No serious cardiac arrhythmias&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major pulmonary problems&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of neurologic disease (except related to brain tumor)&#xD;
&#xD;
          -  No psychosis&#xD;
&#xD;
          -  No impaired cognitive function&#xD;
&#xD;
          -  No significant concurrent medical illness&#xD;
&#xD;
          -  No active infection requiring antibiotic therapy&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate peripheral veins to permit leukapheresis, or placement of indwelling central&#xD;
             vascular access device&#xD;
&#xD;
          -  No hepatitis B or C&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior autoimmune disease&#xD;
&#xD;
          -  Allergy to gentamicin is allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 6 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine) and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Reduction or elimination of corticosteroids&#xD;
&#xD;
          -  Not greater than 0.15 mg/kg/day dexamethasone equivalent&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery is allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Concurrent therapy with acetaminophen, anticonvulsant agents, and headache pain&#xD;
             medications is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta L. Hayes, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immune Therapy, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995 Sep 1;76(5):840-52. doi: 10.1002/1097-0142(19950901)76:53.0.co;2-r.</citation>
    <PMID>8625188</PMID>
  </results_reference>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

